MDxHealth Exits Resolve UTI Business Amid $10.4M Medicare Recoupment Claim; Q1 Losses Worsen

summarizeSummary

MDxHealth is exiting its Resolve UTI business due to reimbursement issues and faces a $10.4 million Medicare recoupment claim, while reporting increased Q1 operating losses and a reduced cash balance, exacerbating prior 'going concern' warnings.

check_boxKey Events

• Discontinuation of Resolve UTI Business

  MDxHealth is discontinuing its Resolve UTI offering and closing its Plano, Texas laboratory operations. This decision was driven by an increasingly uncertain reimbursement landscape and an unexplained policy reversal by its Medicare administrator (Novitas), making the business line unsustainable. Restructuring and exit-related charges are expected.

• $10.4M Medicare Recoupment Claim

  The company received a Medicare contractor recoupment decision from Novitas Solutions totaling approximately $10.4 million related to historical Resolve mdx claims. MDxHealth strongly disagrees with the findings and is vigorously contesting the decision, accounting for it as a contingent liability without a current provision.

• Increased Q1 Operating Losses

  For Q1 2026, MDxHealth reported an operating loss of $7.3 million, a 59% increase year-over-year, and an Adjusted EBITDA loss of $4.3 million, a 226% increase, primarily due to higher operating expenses related to the ExoDx acquisition.

• Reduced Cash Position Post-Earnout

  Cash and cash equivalents were $43.2 million as of March 31, 2026. However, a subsequent $15.0 million earnout payment to Exact Sciences on April 15, 2026, would reduce the pro-forma cash balance to $28.2 million.

auto_awesomeAnalysis

MDxHealth is discontinuing its Resolve UTI business and closing its Plano, Texas lab due to an unsustainable reimbursement landscape and a policy reversal by its Medicare administrator. This strategic exit, while aimed at focusing on core prostate cancer diagnostics, comes with expected restructuring charges and highlights significant operational challenges. Furthermore, the company faces a substantial $10.4 million Medicare recoupment decision, which it is contesting, but represents a material contingent liability given its cash position. These developments, coupled with increased operating losses in Q1 and the company's previously disclosed 'going concern' warning in its 20-F filing, raise serious concerns about its financial stability and ability to navigate regulatory and reimbursement hurdles. The stock is trading near its 52-week low, amplifying the negative impact of this news.